Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Tracy A. Brooks(Roswell Park Comprehensive Cancer Center), Iwao Ojima(Stony Brook University), Hans Minderman(Roswell Park Comprehensive Cancer Center), Kieran L. O’Loughlin(Roswell Park Comprehensive Cancer Center), Ralph J. Bernacki, Paula Pera, Maria R. Baer(University of Maryland, Baltimore)
PubMed
November 1, 2003
Cited by 118
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764